Isomorphic Labs Raises $5B for Clinical Trials
Get up to speed
Isomorphic Labs, an AI drug-discovery platform spun out from Google’s DeepMind, has raised $5 billion in a Series C funding round. This follows a $2.1 billion round in May 2026. The funding, co-led by Greenoaks and Sequoia Capital, aims to advance the company's AI drug-design engine and push its drug pipeline toward clinical trials. The company has yielded positive preclinical results in oncology and immunology, building on DeepMind's AlphaFold protein-folding AI model.
Generated by AI from the reports · Updated 2h ago
Report timeline
Follow the reporting to see the story from different angles.
- The DecoderIsomorphic Labs raises $5 billion in its second mega-round within six months
Isomorphic Labs has raised $5 billion, just six months after a $2.1 billion round. Alphabet's AI drug discovery company, led by Demis Hassabis, plans to use the funding to push its drug pipeline toward clinical trials. The company has no approved drugs yet. The article Isomorphic Labs raises $5 billion in its second mega-round within six months appeared first on The Decoder .
- TechCrunch · AIIsomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round.
Heat trend for this story
- Current, comparable range
- 18
- Peak, comparable range
- 19Nov 18 00:00
- Change over the last 24 hours
- –
The trend only compares the same subjects observed continuously throughout; the range may be smaller than the current heat count. Move the pointer or tap the chart to see hourly heat; use the left and right arrow keys on a keyboard.